Bentley Pharmaceuticals Begins Trading on the New York Stock Exchange

Bentley Pharmaceuticals Begins Trading on the New York Stock
Exchange
- Shares continue trading under the ticker symbol 'BNT' - 


EXETER, N.H., May 12  /PRNewswire-FirstCall/ -- Bentley Pharmaceuticals, Inc. ,
a specialty pharmaceutical company focused on advanced drug-delivery
technologies, which also manufactures and markets generic and branded products
in Europe, today announced that its common stock began trading on the New York
Stock Exchange (NYSE) as James R. Murphy, Chairman, President and CEO of
Bentley rang The Opening Bell(TM).  Shares of the Company's common stock will
continue trading under the ticker symbol, "BNT."

Mr. Murphy, commented, "Bentley's listing on the prestigious NYSE marks a
significant milestone in our growth and development and represents another step
in our ongoing commitment to delivering value to our shareholders.  The NYSE
listing will provide greater visibility and access to a wider investor base. 
We are honored to join the family of NYSE-listed companies and look forward to
continued growth and development on the NYSE," concluded Mr. Murphy.

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
advanced drug delivery technologies and pharmaceutical products. Bentley's
proprietary drug technologies enhance or facilitate the absorption of
pharmaceutical compounds across various membranes. Bentley also manufactures
and markets a growing portfolio of generic and branded pharmaceuticals in
Europe for the treatment of cardiovascular, gastrointestinal, infectious and
neurological diseases through its subsidiaries, Laboratorios Belmac,
Laboratorios Davur and Laboratorios Rimafar; and manufactures and sells active
pharmaceutical ingredients through its subsidiary, Bentley API.

Copies of Bentley Pharmaceuticals' press releases and other information may be
obtained through Bentley's web site at http://www.bentleypharm.com/.

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This press release contains forward looking statements, including without
limitation, statements regarding the effects of the listing of our Common Stock
on the New York Stock Exchange including our visibility to additional investors
and an increase in stockholder base.  These forward- looking statements are
subject to a number of risks and uncertainties that could cause actual results
to differ materially from future results expressed or implied by such
statements.  Factors that may cause such differences include, but are not
limited to, risks associated with expanding generic and branded drug
operations, changes in third-party reimbursement and government mandates which
impact pharmaceutical pricing, actions of third parties, including stock
exchange regulatory authorities and investors, and other uncertainties detailed
in Bentley's most recent Annual Report on Form 10-K and its other subsequent
periodic reports filed with the Securities and Exchange Commission.  Bentley
cautions investors not to place undue reliance on the forward-looking
statements contained in this release.  These statements speak only as of the
date of this document, and Bentley undertakes no obligation to update or revise
the statements, except as may be required by law. 

DATASOURCE: Bentley Pharmaceuticals, Inc.



CONTACT:  Michael D. Price, Vice President and Chief Financial Officer of

Bentley Pharmaceuticals, Inc., [phone]; or Investors: Jonathan Birt,

Lanie Marcus, or Media: Sean Leous, [phone], all of Financial

Dynamics



Web site:  http://www.bentleypharm.com/ 

Copyright